Yiming Angko-B (01541) released interim results, achieved revenue of 254.24 million yuan, and many key clinical trials reached important points

According to the Zhitong Finance App, Yiming Onko-B (01541) announced interim results for the six months ended June 30, 2026, with revenue of 254.24 million yuan (RMB, same below); R&D expenditure was 155 million yuan, a decrease of 7.9% over the previous year.

According to the announcement, revenue for the six months ended June 30, 2026 was RMB 25.424 million, mainly due to payments received in accordance with the licensing and cooperation agreement between the company and Axion Bio, Inc. in 2024.

During the reporting period, the company continued to rapidly advance the development of drug pipelines, and achieved important milestones and achievements in the fields of tumor immunotherapy and autoimmune diseases. Major clinical-stage assets such as IMM01 (tidapecip), IMM0306 (amurefurop α), and IMM2510 (pervilafp α) have made significant progress, and a number of key clinical trials have reached important milestones. At the same time, the company is actively expanding the field of non-tumor treatment, making significant progress in autoimmune diseases, metabolic diseases, cardiovascular diseases and pulmonary hypertension, further unleashing the therapeutic potential of drug candidates.